Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
University of Toronto
$120,000.00
The impact of systemic lupus erythematosus on the expression of placental drug transporters and maternal-fetal drug disposition in a pregnant mouse model of lupus.
FY 2025-26
Summary
Lupus is an autoimmune disease that can cause serious complications during pregnancy. To minimize these potential health risks, lupus patients often need to continue taking medications throughout pregnancy. However, researchers do not fully understand how lupus alters the way in which the placenta processes these medications. The placenta is an organ that connects the mother to the developing fetus and contains specialized proteins called "drug transporters", which act to protect the fetus from exposure to harmful medications. Previous studies in our laboratory have shown that lupus decreases the amount of functional drug transporter proteins in the placenta, which may in turn put the fetus at risk of drug exposure. This further raises questions about which lupus medications can be safely used during pregnancy. To address these concerns, the proposed study will utilize a pregnant mouse model with lupus-like symptoms. Lupus will be induced in female mice by the compound imiquimod, which is known to activate the immune system and generate chronic inflammation. These mice will then be bred to generate a pregnant lupus mouse model. In doing so, we will be able to assess how the expression of placental transporter proteins is altered in an active lupus model. Moreover, we will administer a commonly prescribed lupus medication, hydroxychloroquine, to examine how this drug is distributed, metabolized, and eliminated in pregnancy. This study will provide important information about the risk of fetal drug exposure and drug levels in various organs and tissues. The results of this study will assist clinicians in making safer and more informed decisions about which medications should be prescribed for pregnant patients with lupus. These findings will also help to optimize treatment strategies for pregnant lupus patients, improve maternal-fetal outcomes, and promote healthier pregnancies.
Department
Program
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
559701
Name
Nelles Diana
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Human Development, Child and Youth Health
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
The impact of systemic lupus erythematosus on the expression of placental drug transporters and maternal-fetal drug disposition in a pregnant mouse model of lupus.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Drug Pharmacokinetics; Drug Safety; Drug Transporters; Fetal Drug Exposure; Hydroxychloroquine; Imiquimod-Induced Mouse Model Of Lupus; Lupus Pathology; Maternal-Fetal Health; Placental Biology; Pregnancy Research
Abstract
Lupus is an autoimmune disease that can cause serious complications during pregnancy. To minimize these potential health risks, lupus patients often need to continue taking medications throughout pregnancy. However, researchers do not fully understand how lupus alters the way in which the placenta processes these medications. The placenta is an organ that connects the mother to the developing fetus and contains specialized proteins called "drug transporters", which act to protect the fetus from exposure to harmful medications. Previous studies in our laboratory have shown that lupus decreases the amount of functional drug transporter proteins in the placenta, which may in turn put the fetus at risk of drug exposure. This further raises questions about which lupus medications can be safely used during pregnancy. To address these concerns, the proposed study will utilize a pregnant mouse model with lupus-like symptoms. Lupus will be induced in female mice by the compound imiquimod, which is known to activate the immune system and generate chronic inflammation. These mice will then be bred to generate a pregnant lupus mouse model. In doing so, we will be able to assess how the expression of placental transporter proteins is altered in an active lupus model. Moreover, we will administer a commonly prescribed lupus medication, hydroxychloroquine, to examine how this drug is distributed, metabolized, and eliminated in pregnancy. This study will provide important information about the risk of fetal drug exposure and drug levels in various organs and tissues. The results of this study will assist clinicians in making safer and more informed decisions about which medications should be prescribed for pregnant patients with lupus. These findings will also help to optimize treatment strategies for pregnant lupus patients, improve maternal-fetal outcomes, and promote healthier pregnancies.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Nelles, Diana
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~